RankAlpha logo
Back to Rankings

TVTX

Travere TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The core bullish case improved materially after the April 13, 2026 FDA approval expanded FILSPARI into FSGS, giving Travere a second rare-kidney commercial leg. Primary company materials also showed strong 2025 FILSPARI momentum, with full-year U.S.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.7.
What can break
As of May 4, 2026, no verified Q1 2026 earnings release or 8-K was found in the checked primary sources, leaving revenue/EPS surprise, guidance, and revision signals unavailable [#IR-2026-04-27].
Momentum
91
Value
41
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $43.00 · Bull $52.00 · Bear $34.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $42.71
Why
Momentum91 · Δ7d -0.7
Value41 · Δ7d +0.1
Sentiment50 · Δ7d +1.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
91
34% active weight
Current posture
7d trendSoftening
Δ7d
-0.7
Δ21d
-4.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
50
33% active weight
Current posture
7d trendImproving
Δ7d
+1.6
Δ21d
+4.3
Why this grade

Composite grade B. Momentum 91.5 / Value 41.1 / Sentiment 50.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$4.19B
Beta
0.84
Shares Out
89.47M
P/E (TTM) · Derived
-83.1
P/S (TTM)
7.82
P/FCF (TTM) · Derived
-39.54
Rev YoY
+162.1%
EPS YoY
+135.6%
Gross Margin
+97.6%
Op Margin
-20.9%
Net Debt
$8.29M
Current Ratio
2.75
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology